



Clinical Science Course (CSC) • Basic Science Course (BSC)  
Swiss Society of Ophthalmology

Main program  
**Swiss Eye Week 2026**

**12.–16.01.2026**

Hotel Seepark  
Thun

[swisseyeweek2026.congress-imk.ch](http://swisseyeweek2026.congress-imk.ch)

# Welcome to the Swiss Eye Week 2026 in Thun

Dear members, dear colleagues,

We are delighted to welcome you to **Swiss Eye Week 2026**, which will take place for the first time at the Hotel Seepark in Thun.

The primary goal of Swiss Eye Week is to provide ophthalmologists in training in Switzerland with a high-quality, contemporary, and practice-oriented educational opportunity. In addition, specialists are welcome to refresh and deepen their knowledge by attending the sessions. Once again, we are pleased to offer both the **Basic Science Course (BSC)** and the **Clinical Science Course (CSC)**, running in parallel throughout the week. These courses will be led by outstanding speakers from across the field.

The **Young Swiss Ophthalmologists (YSO)** warmly invite all participants to the Swiss Eye Drink on Monday evening – a relaxed setting for informal exchange. On Thursday evening, all attendees are invited to an apéro with our industry partners, providing an ideal opportunity to cultivate existing contacts and establish new ones.

We look forward to an engaging, productive, and collegial week in Thun, and to welcoming you to another successful edition of Swiss Eye Week.

With our best regards,



**PD Pascal Hasler, MD**

President of the Swiss Society of Ophthalmology (SSO)



**Prof. Beatrice Früh, MD**

Co-Lead Scientific Committee



**PD Moreno Menghini, MD**

Co-Lead Scientific Committee

# General information

<b>Date</b>	January 12-16, 2026
<b>Congress website</b>	<a href="https://swisseyeweek2026.congress-imk.ch">swisseyeweek2026.congress-imk.ch</a>
<b>Venue</b>	Hotel Seepark Seestrasse 47   3602 Thun <a href="https://seepark.ch">seepark.ch</a>   Tel. +41 33 226 12 12
<b>Opening Times</b> <b>Congress Secretariat</b>	Monday: 10:00-17:45   Tuesday: 08:15-18:00   Wednesday: 08:15-19:00 Thursday: 08:15-17:45   Friday: 08:15-16:30
<b>Badges</b>	Participants will receive their personal congress badge at check-in. The badge is valid for the duration of the meeting and must be worn at all times in order to gain entry into the meeting room and the exhibition area.
<b>Credits</b>	Since the Swiss Eye Week 2026 is a continuing education event for resident doctors, no CME credits can be awarded.

<b>Registration fees</b> <b>BSC/CSC</b>	<b>Monday - Friday:</b> <b>early bird until</b> <b>01.01.26</b>	<b>Monday - Friday:</b> <b>late fee from</b> <b>02.01.26</b>	<b>1-day participation:</b> <b>early bird until</b> <b>01.01.26</b>	<b>1-day participation:</b> <b>late fee from</b> <b>02.01.26</b>
Member Young Swiss Ophthalmologists	CHF 1'000.-	CHF 1'050.-	CHF 200.-	CHF 230.-
Non-member YSO (residents)*	CHF 1'500.-	CHF 1'550.-	CHF 320.-	CHF 350.-
Member SSO	-	-	CHF 300.-	CHF 330.-
Non-member specialist / title holder	-	-	CHF 450.-	CHF 480.-

Prices in CHF. Subject to change

\*If registration is submitted early (by 31.12.2025 at the latest) and an application for Young Swiss Ophthalmologists membership is submitted at the same time, the reduced fee for Young Swiss Ophthalmologists members is due.

<b>Cancellation policy</b>	All cancellations must be electronically mailed to <b>IMK</b> . Cancellations received up to December 12, 2025: 50% refund will be made. Cancellations received starting from December 13, 2025: no refund will be made.
<b>Confirmation of Participation</b>	Confirmations of participation will be sent by email after the event
<b>Contact SSO</b>	<a href="https://www.sog-ss0.ch">www.sog-ss0.ch</a>   <a href="mailto:sog@imk.ch">sog@imk.ch</a>
<b>Scientific Committee</b>	Prof. Beatrice Früh, MD: Lead Clinical Science Course PD Moreno Menghini, MD: Lead Basic Science Course
<b>Professional Congress Organizer (PCO)</b>	<b>IMK</b> Institute for medicine and communication Ltd. Harald F. Grossmann Münsterberg 1   4001 Basel Tel. +41 61 561 53 53   <a href="https://www.imk.ch">www.imk.ch</a>   <a href="mailto:congress@imk.ch">congress@imk.ch</a>

**Monday, January 12, 2026**

\* including 15 minute break

12:45-14:00	Lunch Break   Registration	
14:00-15:45*	<b>Ocular / Retinal Development</b>	Pascal Escher, Bern
15:45-16:00	Coffee Break	
16:00-17:45*	<b>Genetics</b>	Pascal Escher, Bern
From 17:45	Swiss Eye Drink organized by YSO	

**Tuesday, January 13, 2026**

09:00-10:45*	<b>Pharmacology</b>	Nicolas Waldmann, Reinach
10:45-11:00	Coffee Break	
11:00-12:45*	<b>Vitreous / Retina / RPE</b>	Moreno Menghini, Lugano
12:45-14:00	Lunch Break	
14:00-15:45*	<b>Electrophysiology / Echography</b>	Johannes Fleischhauer, Zurich
15:45-16:00	Coffee Break	
16:00-17:45*	<b>Diffusion Barriers in the Eye</b>	Lazaros Konstantinidis, Lausanne

**Wednesday, January 14, 2026**

09:00-10:45*	<b>Retrochiasmal Pathways</b>	Mathias Abegg, Bern
10:45-11:00	Coffee Break	
11:00-12:45*	<b>Conjunctiva and Cornea</b>	Farhad Hafezi, Zurich
12:45-14:00	Lunch Break	
14:00-15:45*	<b>Ocular Microbiology / Ocular Pathology</b>	Alexandre Moulin, Lausanne
15:45-16:00	Coffee Break	
16:00-16:45	<b>Aqueous Humor Dynamics</b>	Kaweh Mansouri, Lausanne
16:45-17:00	Short Break	
17:00-17:45	<b>Perimetry / Octopus</b>	Kaweh Mansouri, Lausanne

**Thursday, January 15, 2026**

09:00-10:45*	<b>Pharmaceutical Aspects of Ophthalmic Medication</b>	Stefan Mühlebach, Aarau
10:45-11:00	Coffee Break	
11:00-12:45*	<b>Fundamentals in Physics and Optics</b>	Thomas Hofmann, Basel
12:45-14:00	Lunch Break	
14:00-15:45*	<b>Statistics</b>	Ciara Bergin, Lausanne
15:45-16:00	Coffee Break	
16:00-17:45*	<b>Immunology Applied to Ophthalmology</b>	Christoph Tappeiner, Olten
From 17:45	Apero in the industry exhibition	

**Friday, January 16, 2026**

09:00-10:45*	<b>Lens</b>	Tim Beltraminelli, Lausanne
10:45-11:00	Coffee Break	
11:00-11:45	<b>Lid and Lacrimal System</b>	David Goldblum, Bern
11:45-12:00	Short Break	
12:00-12:45	<b>Ocular Motility</b>	Simone Bruschi, Nottingham, UK
12:45-14:00	Lunch Break	
14:00-14:45	<b>Optic Nerve and Chiasm</b>	Simone Bruschi, Nottingham, UK

## Monday, January 12, 2026

\* including 15 minute break

11:00-12:45*	<b>Cornea</b>	Beatrice Früh, Bern
12:45-14:00	Lunch Break	
14:00-15:45*	<b>Physiology of the Retina and Electroretinography, ERG</b>	Günter Niemeyer, Zurich
15:45-16:00	Coffee Break	
16:00-17:45*	<b>Cataract</b>	Ulrike Schneider, Basel
From 17:45	Swiss Eye Drink organized by YSO	

## Tuesday, January 13, 2026

09:00-10:45*	<b>Conjunctiva</b>	Wolfgang Bernauer, Zurich
10:45-11:00	Coffee Break	
11:00-12:45*	<b>Retinoblastoma</b>	Francis Munier, Lausanne
12:45-14:00	Lunch Break	
14:00-15:45*	<b>Neuroophthalmology</b>	Hilary Grabe, Bern
15:45-16:00	Coffee Break	
16:00-17:45*	<b>Diabetic Retinopathy</b>	Johannes Fleischhauer, Zurich

## Wednesday, January 14, 2026

09:00-10:45*	<b>Therapeutic Refractive Surgery</b>	Farhad Hafezi, Zurich
10:45-11:00	Coffee Break	
11:00-12:45*	<b>Makula</b>	Pascal Hasler, Basel
12:45-14:00	Lunch Break	
14:00-15:45*	<b>Glaucoma</b>	Kaweh Mansouri, Lausanne
15:45-16:00	Coffee Break	
16:00-16:45	<b>Hereditary Retinal Disorders</b>	Christina Gerth-Kahlert, Zurich
16:45-17:00	Break	
17:00-17:45	<b>Pediatric Ophthalmology</b>	Christina Gerth-Kahlert, Zurich
17:45-18:00	Break	
18:00-18:45	<b>Strabism</b>	Christina Gerth-Kahlert, Zurich

## Thursday, January 15, 2026

09:00-10:45*	<b>Orbita</b>	Ivan Haefliger, Basel
10:45-11:00	Coffee Break	
11:00-12:45*	<b>Corneal Imaging</b>	Theo G. Seiler, Bern
12:45-14:00	Lunch Break	
14:00-15:45*	<b>Vitreous and Retina</b>	Jelena Potic, Lausanne
15:45-16:00	Coffee Break	
16:00-17:45*	<b>Uveitis</b>	Carl P. Herbort Jr., Lausanne Ioannis Pappasavvas, Lausanne
From 17:45	Apero in the industry exhibition	

## Friday, January 16, 2026

09:00-10:45*	<b>Lid and Lacrimal System</b>	David Goldblum, Bern
10:45-11:00	Coffee Break	
11:00-12:45*	<b>Pigmented fundus tumours: DD and management</b> <b>Vascular fundus tumours: DD and management</b>	Ann Schalenbourg, Lausanne
12:45-14:00	Lunch Break	
14:00-15:45*	<b>Quiz + Tricks for CSC and EBO Exams</b>	Christian Prünke, Biel/Bienne Tim Beltraminelli, Lausanne
15:45-16:15	<b>FMH Title – Step by Step</b>	Lilly Khamsy, Sion

# Partners 2026

We would like to thank all our partner companies for their generous support!

---

## Diamond Partner 2026



## Premium Partner 2026



## Partner 2026



## Supporter 2026



# Jahreskongress 2026 Congrès annuel

Schweizerische Ophthalmologische Gesellschaft  
Société Suisse d'Ophtalmologie

SOG  
SSO

26. – 28.08.2026

SwissTech Convention Center  
Lausanne

[sog-sso2026.congress-imk.ch](http://sog-sso2026.congress-imk.ch)



# EYLEA® 8mg<sup>1-3</sup>

- ✓ Schnelle Flüssigkeitskontrolle\*
- ✓ Anhaltende Visusgewinne
- ✓ Grosse Behandlungsfreiheit

# Still EYLEA® but MORE<sup>1</sup>



Bei nAMD und DME<sup>1</sup>

\* Schnelle und auf tiefem Niveau gegenüber Baseline anhaltende CRT-Abnahme.

**Referenzen:** **1.** Fachinformation EYLEA® 8mg, [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch) **2.** Lanzetta P, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. *Lancet* 2024;403(10432):1141–1152 and Appendix. **3.** Brown DM, et al. Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, noninferiority, phase 2/3 trial. *Lancet* 2024;403(10432):1153–1163 and Appendix.

Die referenzierten Daten, resp. Publikationen werden auf Anfrage zur Verfügung gestellt.

### Kurzfachinformation EYLEA® (Aflibercept) 8mg

**Z:** 8mg Aflibercept in 70µl Injektionslsg. Hilfsstoffe: Arginini hydrochloridum, Histidinum, Histidini hydrochloridum monohydrum, Polysorbatum 20, Saccharum, Aqua ad injectabile. **I:** Behandlung von neovaskulärer altersbedingter Makuladegeneration (nAMD) und Diabetischem Makulödem (DME) bei Erwachsenen. **DA:** nAMD und DME: Die Behandlung mit EYLEA® 8mg wird mit einer Injektion pro Monat (alle 4 Wochen) für 3 aufeinanderfolgende Dosen begonnen. Anschliessend können die Injektionsintervalle, basierend auf der Beurteilung der Ergebnisse der Sehschärfepfprüfung und der morphologischen Untersuchungen, auf bis zu alle 16 Wochen und danach auf bis zu alle 20 Wochen verlängert werden. Die Behandlung mit EYLEA® 8mg in Intervallen von weniger als 8 Wochen wurde, abgesehen von der Initiationsphase mit 3 aufeinanderfolgenden 4-wöchentlichen Dosen, nicht untersucht. Es sind keine Kontrolluntersuchungen zwischen den Injektionen erforderlich. Die Häufigkeit der Kontrolluntersuchungen sollte sich nach dem Zustand des Patienten und nach dem Ermessen des Arztes richten. **KI:** Bekannte Überempfindlichkeit gegenüber Aflibercept oder einem der Hilfsstoffe, okuläre oder periokuläre Infektion, aktive oder vermutete intraokuläre Entzündung, SS, Stillzeit. **V:** Endophthalmitis, Erhöhungen des Augeninnendrucks, besondere Vorsicht bei Patienten mit nicht ausreichend therapiertem Glaukom oder mit einem Schlaganfall, TIA oder einem Myokardinfarkt in den letzten 6 Mte. **IA:** Es wurden keine Interaktionsstudien mit EYLEA® durchgeführt. **UW:** Häufig: Katarakt, Mouches volantes, Bindehautblutung, verminderte Sehschärfe, Glaskörperabhebung, Einblutung in die Retina, erhöhter Augeninnendruck, Augenschmerzen, Keratitis punctata, Hornhautabrasion, Hypersensitivitätsreaktionen. **P:** 1 Durchstechflasche und 1 Filternadel oder 1 Fertigspritze mit OccuClick® Dosierungssystem. Verkaufskategorie: B. Weiterführende Informationen entnehmen Sie bitte der Fachinformation auf [www.swissmedicinfo.ch](http://www.swissmedicinfo.ch). Vertrieb: Bayer (Schweiz) AG, 8045 Zürich. [MA-AFL\_8mg-CH-0062-110.2024]